Acute Ischaemic Stroke in a COVID-19 Patient on Baricitinib - A Causal Effect or a Multifactorial Relationship?
DOI:
https://doi.org/10.33102/mjosht.v8i.265Keywords:
Ischaemic Stroke, COVID-19, Arterial Thrombosis, BaricitinibAbstract
Coronavirus disease 2019 (COVID-19), a multisystemic disorder caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been associated with both venous and arterial thromboses. The hypercoagulable state of the disease poses a challenge to the patient’s management. We herein report a case of acute ischaemic stroke in a COVID-19 patient who had been treated with three days of Baricitinib, an immunotherapy that can potentially augment the thrombotic risks. The case highlights the dilemma faced when initiating immunotherapy in a COVID-19 patient and emphasises the importance of evaluating the patient’s thrombotic risks, balanced against the benefit of immunotherapy, to facilitate the selection of ideal candidates for the immunotherapy.
Downloads
References
Luo, W., Liu, X., Bao, K., & Huang, C. (2022). Ischemic stroke associated with COVID-19: a systematic review and meta-analysis. Journal of Neurology, 269(4), 1731–1740. https://doi.org/10.1007/s00415-021-10837-7
Tan, Y. K., Goh, C., Leow, A. S. T., Tambyah, P. A., Ang, A., Yap, E. S., Tu, T. M., Sharma, V. K., Yeo, L. L. L., Chan, B. P. L., & Tan, B. Y. Q. (2020). COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. Journal of Thrombosis and Thrombolysis, 50(3), 587–595. https://doi.org/10.1007/s11239-020-02228-y
Zakeri, A., Jadhav, A. P., Sullenger, B. A., & Nimjee, S. M. (2021). Ischemic stroke in COVID-19-positive patients: An overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. Journal of NeuroInterventional Surgery, 13(3), 202–206. https://doi.org/10.1136/neurintsurg-2020-016794
Nannoni, S., de Groot, R., Bell, S., & Markus, H. S. (2021). Stroke in COVID-19: A systematic review and meta-analysis. International Journal of Stroke, 16(2), 137–149. https://doi.org/10.1177/1747493020972922
Pawelczyk, M., Kaczorowska, B., & Baj, Z. (2017). The impact of hyperglycemia and hyperlipidemia on plasma P-selectin and platelet markers after ischemic stroke. Archives of Medical Science, 13(5), 1049–1056. https://doi.org/10.5114/aoms.2017.65816
Qureshi, A. I., Baskett, W. I., Huang, W., Shyu, D., Myers, D., Raju, M., Lobanova, I., Suri, M. F. K., Naqvi, S. H., French, B. R., Siddiq, F., Gomez, C. R., & Shyu, C. R. (2021). Acute Ischemic Stroke and COVID-19: An Analysis of 27 676 Patients. Stroke, March, 905–912. https://doi.org/10.1161/STROKEAHA.120.031786
Klein, A. P., Yarbrough, K., & Cole, J. W. (2021). Stroke, Smoking and Vaping: The No-Good, the Bad and the Ugly. Annals of public health and research, 8(1), 1104.
Jorgensen, S. C. J., Tse, C. L. Y., Burry, L., & Dresser, L. D. (2020). Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19. Pharmacotherapy, 40(8), 843–856. https://doi.org/10.1002/phar.2438
Kalil, A. C., & Stebbing, J. (2021). Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. The Lancet Respiratory Medicine, 9(12), 1349–1351. https://doi.org/10.1016/S2213-2600(21)00358-1
Marconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Alatorre-Alexander, J., de Cassia Pellegrini, R., Estrada, V., Som, M., Cardoso, A., Chakladar, S., Crowe, B., Reis, P., Zhang, X., Adams, D. H., Ely, E. W., … Zirpe, K. (2021). Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. The Lancet Respiratory Medicine, 9(12), 1407–1418. https://doi.org/10.1016/S2213-2600(21)00331-3
Kalil, A.C., Patterson, T.F., Mehta, A.K., Tomashek, K.M., Wolfe, C.R., Ghazaryan, V., Marconi, V.C., Ruiz-Palacios, G.M., Hsieh, L., Kline, S. and Tapson, V., 2021. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine, 384(9), pp.795-807. https://doi.org/10.1056/nejmoa2031994
Spyropoulos, A. C., Cohen, S. L., Gianos, E., Kohn, N., Giannis, D., Chatterjee, S., Goldin, M., Lesser, M., Coppa, K., Hirsch, J. S., McGinn, T., & Barish, M. A. (2021). Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalised patients with COVID-19. Research and Practice in Thrombosis and Haemostasis, 5(2), 296–300. https://doi.org/10.1002/rth2.12486
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Wei Ming Tan, Hana Maizuliana Solehan, Sarah Zulaikha Samad, M Firdaus A Bakar, Nor Safiqah Sharil, Nur Ezzaty Mohammad Kazmin, Fatimah Zanirah, Koon Ket Sia
This work is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of this article will be vested to author(s) and granted the journal right of first publication with the work simultaneously licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license, unless otherwise stated.
